For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and Tafamidis meglumine represents a true breakthrough . These innovative therapies preserve the transthyretin protein, slowing its harmful build-up and reducing the impact of the disease . People are now reporting positive outc